Sanofi moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks for a deal that values the business at $17.4 billion, including debt.
Sanofi moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks for a deal that values the business at $17.4 billion, including debt.